Patients with renal cell carcinoma (RCC) are at lower risk of end-stage renal disease (ESRD) requiring renal replacement therapy (dialysis or transplant) if they undergo partial rather than radical nephrectomy, a new study suggests.
The IKCC is working with the European Association of Urology (EAU) on Guidelines for kidney cancer. Several countries already have such guidelines. If there is an opportunity to create clinical guidelines in your own country, it would be worthwhile to build upon the work done in other countries.
Overall message from ASCO 2015 is that the field of cancer treatment is changing rapidly. Words such as “practice-changing” and “breakthrough” were heard often, but there is also room from some caution while we await more information from upcoming trials.
Urine aquaporin-1 (AQP1) and perilipin-2 (PLIN2) seem to have utility as biomarkers for diagnosing malignant clear cell or papillary renal cell carcinoma (RCC) in a screening paradigm, according to a study published online March 19 in JAMA Oncology.
World Health Organization (WHO) today issued a public statement calling for the disclosure of results from clinical trials for medical products, whatever the result. The move aims to ensure that decisions related to the safety and efficacy of vaccines, drugs and medical devices for use by populations are supported by the best available evidence.
A course for patient advocates explaining how clinical studies are conducted and how they can help with design of such studies, and recruiting participants.
